However, largely due to the administrative and logistical challenge of the enrollment process, the GIC has not been able to move forward with a plan
Additionally, the company is asking for the associated lawsuits to be dismissed, under a 702 judgment, based on the adequacy of the FDA-approved product labeling and the lack of admissible expert testimony on general causation. This is a common defense tactic in mass litigation, like this MDL for Ozempic and other GLP-1 drugs
2020;45(Suppl 1):43-60
January 24, 2024- Lynn Hill, a resident of Tennessee, filed an ozempic lawsuit complaint against Novo Nordisk
For individuals with obesity or metabolic challenges, semaglutide may provide a more controlled and effective solution
What to Expect When Starting Semaglutide Starting semaglutide involves finding the right dose